Pros | ![]() Among most bought funds within the category. | ![]() Larger AUM within category. ![]() Beats FD returns for both 3Y & 5Y duration. | ||
Cons | - | ![]() 5Y returns in the bottom 25% of the category. ![]() 3Y returns in the bottom 25% of the category. |
INDMoney rank | - | 7/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 1 Years | 12 Years | ||
Fund Size | 1936 Cr | 8737 Cr | ||
Min Investment | SIP ₹100 Lumpsum ₹100 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 0.87% | 0.89% | ||
Exit Load | 1% | 1% | ||
Benchmark Index | BSE Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 31 | 41 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (10.97%) Divi's Laboratories Ltd (8.81%) Glenmark Pharmaceuticals Ltd (7.42%) Cipla Ltd (6.33%) Lupin Ltd (5.98%) | Sun Pharmaceuticals Industries Ltd (12.22%) Divi's Laboratories Ltd (7.55%) Lupin Ltd (5.93%) Cipla Ltd (5.69%) Dr Reddy's Laboratories Ltd (5.69%) | ||
No of Sectors | 2 | 1 | ||
Top 3 Sectors | Health (97.68%) Basic Materials (2.32%) | Health (100%) | ||
Equity % | 98.2% | 99.45% | ||
Debt % | - | - | ||
P/E | 44.94 | 37.97 | ||
P/B | 6.81 | 6.05 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | -2.2% | -2.9% | ||
3-Month Return | 6.5% | 2.14% | ||
6-Month Return | 15.36% | 11.36% | ||
1-Year Return | 13.58% | 2.57% | ||
3-Year Return | - | 24.41% | ||
5-Year Return | - | 19.46% |
Sharpe | - | 1.2 | ||
Alpha | - | 1 | ||
Beta | - | 0.9 | ||
Standard Deviation | - | 14.63 | ||
Information Ratio | - | -0.22 |
Description | HDFC Pharma and Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Nikhil Mathur,Dhruv Muchhal | Sailesh Raj Bhan,Kinjal Desai |